No causal link between the supply of GLP ‐1 receptor agonists and antidepressants: Real‐world evidence from the Australian Pharmaceutical Benefits Scheme

Ähnliche Einträge

• Psychiatric effects of GLP ‐1 receptor agonists: A systematic review of emerging evidence
  von: Brianna Sa, et al.
  Veröffentlicht: (2025)
• Effectiveness and safety of GLP ‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study
  von: Flora Lambert, et al.
  Veröffentlicht: (2025)
• GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
  von: Tommaso Bucci, et al.
  Veröffentlicht: (2025)
• Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety
  von: Hans Johnson, et al.
  Veröffentlicht: (2025)
• The extent and predictors of off‐label use of GLP ‐1 receptor agonists for weight loss management
  von: Zbigniew Siudak, et al.
  Veröffentlicht: (2025)